Emerging markets show limited appetite for premium international brands
This article was originally published in Scrip
The emerging markets have proved a disappointment over the last couple of years. Pharmaceutical multinationals had been hoping that they would help fill revenue gaps resulting from patient expiries of key products. This has not proved the case, and a recent survey shows that things could get even tougher, with few consumers willing to pay extra for expensive international brands.